Regular Article
Effect of Lactobacillus casei on the Absorption of Nifedipine from Rat Small Intestine

https://doi.org/10.2133/dmpk.22.96Get rights and content

Summary:

Lactobacillus casei Shirota strain (L. casei) has a modulating effect on the production of cytokines, which often play important roles in drug metabolism, in the inflamed intestinal mucosa. We evaluated the effect of L. casei administered orally in advance for 4 weeks on the absorption of nifedipine from the rat small intestine. The maximum concentration of nifedipine in plasma after administration into the intestinal loop (0.8 mg/kg) was significantly higher in L. casei-treated rats (3.26 μg/mL) than in those untreated rats (2.33 μg /mL) by 40%. Accordingly, the bioavailability of nifedipine was tended to be higher in the former, while the effect of L. casei on the disposition of intravenously administered nifedipine was negligible. We also found that the availability of nifedipine for the passage through the intestinal mucosa was significantly increased in L. casei-treated rats from the single-pass intestinal perfusion experiments. Therefore, it is likely that the exposure to nifedipine after its administration into rat intestine was increased by oral ingestion of L. casei due to an increase in absorption by increased intestinal availability (decreased metabolic extraction) during passage through the intestinal mucosa. This study has suggested that L. casei has some effect on the metabolic activity in the intestinal mucosa, though it seems to be only mild.

References (27)

  • T. Matsuzaki et al.

    Antidiabetic effects of an oral administration of Lactobacillus casei in a non-insulin-dependent diabetes mellitus (NIDDM) model using KK-Ay mice

    Endocr. J.

    (1997)
  • T. Matsuguchi et al.

    Lipoteichoic acids from Lactobacillus casei strains elicit strong tumor necrosisi factor alpha-inducing activities in macrophages through Toll-like receptor 2

    Clin. Diagn. Lab. Immunol.

    (2003)
  • K. Kitaichi et al.

    Down-regulation of cytochrome P450 proteins and its activities by Shiga-like toxin II from Escherichia coli O157:H7

    Biochem. Pharmacol.

    (2002)
  • Cited by (16)

    • The gut microbiota contributes to the modulation of intestinal CYP3A1 and P-gp in streptozotocin-induced type 1 diabetic rats

      2021, European Journal of Pharmaceutical Sciences
      Citation Excerpt :

      The probiotic Escherichia coli Nissle 1917 affected CYP450 expression along the gastrointestinal tract of rats (Matuskova et al., 2010). Oral administration of Lactobacillus casei changed the expression or activity of CYP1A1, CYP2E1 and CYP3A9 in rats (Matuskova et al., 2011; Kato et al., 2007). The gut microbiota produces dozens of metabolites, such as short-chain fatty acids (SCFAs), amino acid metabolites and secondary bile acids, which have systemic effects on the host.

    • The role of gut microbiota in the pharmacokinetics of antihypertensive drugs

      2018, Pharmacological Research
      Citation Excerpt :

      A recent study suggested that gut microbiota may modulate the metabolic activity of the intestinal mucosa. According to the report by Kato et al. [97], the probiotic bacterial species Lactobacillus casei seems to affect metabolic activity, probably the CYP3A4 enzyme activity in the intestinal mucosa. In that study, rats received L. casei orally for 4 weeks and nifedipine absorption was then evaluated in the rat small intestine.

    View all citing articles on Scopus
    View full text